MyoStrain provides innovative solutions to help meet the clinical needs of physicians and providers. From early cardiac detection to long-term patient monitoring, MyoStrain collaborates with healthcare providers to standardize cardiac patient management and help prevent adverse events for patients at risk of heart failure.
Today, cardiologists have several therapies to protect the heart but lack the visibility needed to quantify cardio-toxicity or manage the effects of cardio-protective therapy without interrupting cancer treatment.
MyoStrain enables physicians reliably measure the cardio-toxic effects of chemotherapy in cancer patients. This helps physicians to determine cardio-protective agents and dosage, as well as monitor and manage treatment.¹
As much as 40% of catheterizations performed are false positive and 15% are false negative.² Today, long exam times and/or poor information make it difficult to quickly or efficiently triage patients. This inefficiency in the ER results in waste from unnecessary procedures and suboptimal care.
MyoStrain uniquely identifies ischemia by providing a rapid and noninvasive stress test via a six-heartbeat MRI scan. This can help improve workflow efficiency, reduce the number of unnecessary procedures, and provide optimal care.
It is estimated that nearly half of Americans will have some form of cardiovascular disease by 2035.³ Without the ability to test for the effects of chronic diseases early and initiate cardiac preventative treatment, the progression of dysfunction goes unnoticed until cardiac symptoms occur.
MyoStrain helps physicians identify patients at risk of heart failure before adverse symptoms occur by providing visibility into the early progression of myocardial dysfunction across 13 chronic disease states.⁴ Physicians may initiate a proactive management approach to address at-risk patients early and prevent heart failure.
Today's diagnostic tests are insensitive to the progression of dysfunction. As a result, physicians are blind to the changing effects of various treatments on the heart. This complicates physicians' ability to manage and optimize treatment, as acute heart failure patients may be taking an average of 6 different drugs with potentially interacting effects.⁵
MyoStrain provides data-driven insight to help physicians select and dose therapy effectively. By quantifying the effects of treatment over time, MyoStrain enables physicians to focus on reducing re-hospitalizations and improving patient quality of life.
1. Steen H, et al. CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment. ESC Congress 2019. P3554.
2. Korosglou G, et al. J Am Coll Cardiol 2011.
3. American Heart Association. CVD Burden Report 2017.
4. Montenbruck M, et al. CMR fast-SENC segmental intramyocardial LV strain detects heart disease progression based on ACC/AHA Heart Failure stage before global longitudinal strain or ejection fraction. ESC Congress 2019. P600.
5. Custodis F, et al. Patient Prefer Adherence 2016. doi:10.2147/PPA.S113912